Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Gastrointestinal Stromal Tumor
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Neoplasm
Interventions
Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Conditions
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Best Practice, Laboratory Procedure, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 13 more
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
Regorafenib
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Including Dallas, TX, Ocala, FL, Denver, CO, Florida
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Aurora, Colorado • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Laguna Hills, California • Los Angeles, California • New Haven, Connecticut + 17 more
Conditions
Gastrointestinal Stromal Tumors
Interventions
Sunitinib, Regorafenib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Placebo
Drug · Other
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more
Conditions
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
regorafenib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Jacksonville, Florida • Chicago, Illinois + 4 more
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer
Interventions
Laboratory Biomarker Analysis, Regorafenib
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
Buffalo, New York • Rocherster, New York • Columbus, Ohio
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Conditions
Dietary Fats, Pharmacokinetics
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brighton, Massachusetts
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Conditions
Liver Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Conditions
Macular Degeneration
Interventions
Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
Drug · Procedure
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
Conditions
Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Regorafenib, Venetoclax
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California